A $2.1 million grant from the National Institutes of Health will allow University of Arizona Health Sciences researchers to study the links between knee structure changes and clinical outcomes in people with osteoarthritis.
The U.S. health regulator on January 13 approved Zoetis Inc,’s once-a-month injection to treat pain in cats with osteoarthritis, a common but difficult-to-diagnose condition that affects the joints in older cats.
Eli Lilly and Pfizer announced Oct. 27 that they ceased the development of tanezumab, a pain drug the two companies had been developing for osteoarthritis.
Shares of Flexion Therapeutics soared in trading on Oct. 11 after Pacira Biosciences announced the acquisition of the Burlington, Massachusetts-based biopharmaceutical company for $427 million in cash.
Belgium-based Bone Therapeutics’ Phase III osteoarthritis study using the company’s enhanced viscosupplement JTA-004 failed to meet primary and critical secondary endpoints.
San Francisco-based Unity Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology.
South San Francisco-based Unity Biotechnology reported that the 12-week results from the company’s Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
Anika Therapeutics Inc. announced results from the company’s CINGAL 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration.
Anika announced a research collaboration with the Institute of Integrative Biology at the University of Liverpool to develop an injectable mesenchymal stem cell therapy for osteoarthritis.
The Korea Ministry of Food and Drug Safety granted marketing approval for Invossa-K Inj., the world’s first cell and gene therapy for degenerative arthritis.